Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun 1;82(6):551-559.
doi: 10.1001/jamaneurol.2025.0850.

Aspirin Continuation or Discontinuation in Surgically Treated Chronic Subdural Hematoma: A Randomized Clinical Trial

Maria Kamenova  1   2 , Lea Pacan  2 , Christian Mueller  2   3 , Michael Coslovsky  4 , Katharina Lutz  5 , Serge Marbacher  6 , Manuel Moser  7 , Anne-Katrin Hickmann  8 , Christian Zweifel  9 , Raphael Guzman  1   2 , Luigi Mariani  1   2 , Jehuda Soleman  1   2 ; SECA Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Aspirin Continuation or Discontinuation in Surgically Treated Chronic Subdural Hematoma: A Randomized Clinical Trial

Maria Kamenova et al. JAMA Neurol. .

Abstract

Importance: Discontinuation of low-dose acetylsalicylic acid (ASA) during the perioperative phase of treatment for chronic subdural hematoma (cSDH) may reduce recurrence rates but may also increase the risk of cardiovascular or thromboembolic events. However, the efficacy and safety of discontinuing ASA in this patient population remain unclear.

Objective: To assess the risk of recurrence of cSDH and cardiovascular events in patients undergoing surgical treatment of cSDH with continuous vs discontinuous ASA treatment.

Design, setting, and participants: The SECA (Surgical Evacuation of Chronic Subdural Hematoma and Aspirin) trial was an investigator-initiated, multicenter, placebo-controlled randomized clinical trial conducted from February 2018 to June 2023 at 6 neurosurgical centers in Switzerland. Adults undergoing burr hole drainage for cSDH and receiving ASA treatment prior to cSDH onset were included. Of 1363 screened patients, 155 were included. Both assessors and participants were blinded to the treatment arms.

Intervention: Participants were randomized 1:1 to receive either continuous ASA or placebo for 12 days during the perioperative phase.

Main outcome and measures: The main outcome was the recurrence rate of cSDH necessitating reoperation within 6 months. An intention-to-treat analysis was performed, calculating risk differences. Secondary outcomes were cardiovascular or thromboembolic events, other bleeding events, and mortality.

Results: Of 155 participants, 78 were assigned to continuous ASA and 77 to placebo treatment. The mean (SD) participant age was 77.9 (8.2) years and 77.6 (9.7) years for the ASA and placebo groups, respectively, and 25 participants (16.1%) were female. A primary outcome event occurred in 13.9% of participants for the ASA group and 9.5% for the placebo group (weighted risk difference, 4.4%; 95% CI, -7.2% to 15.9%; P = .56). The incidence of any cardiovascular or thromboembolic event was 0.27 per person half-year in the ASA group and 0.28 in the placebo group. The incidence of a cardiovascular event indicating ASA treatment was 0.02 per person half-year in the ASA group and 0.06 in the placebo group. Other bleeding events showed an incidence of 0.10 per person half-year in the ASA group and 0.08 in the placebo group. All-cause mortality occurred at an incidence of 0.06 per person half-year in the ASA group and 0.03 in the placebo group.

Conclusions and relevance: The SECA randomized clinical trial suggests that discontinuing ASA treatment did not reduce the recurrence rate of surgically treated cSDH within 6 months. Recurrence risk estimates for continuous ASA treatment in this trial were distinctly lower than previously reported.

Trial registration: ClinicalTrials.gov Identifier: NCT03120182.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Mueller reported receiving research support from the KTI, the Swiss Heart Foundation, the Swiss National Science Foundation, the University Hospital Basel, and the University of Basel during the conduct of the study; receiving research support from Abbott, Astra Zeneca, Beckman Coulter, Boehringer Ingelheim, Brahms, Idorsia, LSI Medience Corporation, Novartis, Ortho Clinical Diagnostics, QuidelOrtho Corporation, Roche, Siemens, SpinChip Diagnostics, Singulex, and SphingoTec outside the submitted work; and speaker or consulting honoraria paid to his institution from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Idorsia, Novartis, Osler, Roche, SpinChip, and Sanofi. Dr Coslovsky reported serving as an independent statistician for data monitoring committees on the ELAN and MOSES trials. Dr Soleman reported grants from the Swiss National Foundation, the Propatient Foundation, and Gottfried und Julia Bangerter-Rhyner-Stiftung during the conduct of the study. No other disclosures were reported.

References

    1. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011;112(2):292-318. doi: 10.1213/ANE.0b013e318203f38d - DOI - PubMed
    1. Möllmann H, Nef HM, Hamm CW. Clinical pharmacology: antiplatelet therapy during surgery. Heart. 2010;96(12):986-991. doi: 10.1136/hrt.2008.155655 - DOI - PubMed
    1. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96(8):2751-2753. doi: 10.1161/01.CIR.96.8.2751 - DOI - PubMed
    1. Nielsen JD, Holm-Nielsen A, Jespersen J, Vinther CC, Settgast IW, Gram J. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy–a prospective, randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol. 2000;34(3):194-198. doi: 10.1080/003655900750016580 - DOI - PubMed
    1. Ducruet AF, Grobelny BT, Zacharia BE, et al. The surgical management of chronic subdural hematoma. Neurosurg Rev. 2012;35(2):155-169. doi: 10.1007/s10143-011-0349-y - DOI - PubMed

Publication types

Associated data